-
Tropisetron Hydrochloride: Receptor–Transporter Insight
2026-08-17
Tropisetron Hydrochloride is more than a 5-HT3 receptor antagonist: it is a useful probe for separating receptor pharmacology from renal transporter effects. This article explains how to design, interpret, and connect these assay domains without conflating potency, mechanism, or translational relevance.
-
Procainamide Hydrochloride Research Workflows
2026-08-16
Procainamide Hydrochloride supports integrated cardiac electrophysiology, immunomodulation, and oncology workflows rather than serving only as a conventional channel-blocking control. This guide translates its Nav1.5 activity, DNMT1-related effects, and cisplatin combination evidence into practical assay designs with defined controls and troubleshooting steps.
-
A40926: From Biosynthesis to Assay Design
2026-08-15
A40926 is a dalbavancin precursor whose biosynthetic regulation offers a powerful framework for interpreting antibacterial data. This article connects engineered production, mechanism, MIC context, and assay design for more reproducible research.
-
Native Protein Gel Electrophoresis with K4142
2026-08-14
Use native protein gel electrophoresis to resolve acidic proteins while retaining conformation, oligomeric state, and enzymatic activity. Kit K4142 combines standardized gel reagents with practical workflows for protein purification and identification, activity assays, and mechanistic studies.
-
Gepotidacin Workflow for Antibacterial Research
2026-08-14
Build more informative antibacterial studies with Gepotidacin (GSK2140944), from broth microdilution and gyrase assays to intracellular Staphylococcus aureus models. The workflow emphasizes solvent control, matched extracellular and intracellular readouts, and PK/PD-aware interpretation for antibiotic resistance research.
-
SU 5402 Workflows for RTK Signaling Studies
2026-08-13
SU 5402 enables controlled dissection of VEGFR2, FGFR1, and PDGFRβ signaling across oncology assays and emerging human sensory-neuron models. This practical guide connects phospho-signaling, cell cycle arrest, apoptosis assay design, and latency-model validation while separating established evidence from testable extensions.
-
Toremifene in Prostate Cancer Research Workflows
2026-08-13
Toremifene provides a reversible estrogen-receptor perturbation tool for connecting hormone-responsive phenotypes with metastasis-relevant assays. This workflow pairs dose-response analysis with STIM1-dependent calcium, migration, invasion, and protein-stability measurements while keeping pathway conclusions appropriately hypothesis-driven.
-
Anti-RPS6 antibody for signaling & ribosome studies
2026-08-12
Use the Anti-RPS6 (7B10) Mouse Monoclonal Antibody to connect growth signaling with protein synthesis, ribosome-associated biology, and phenotype in cultured cells or organoids. Its validated-use profile across Western blot, ICC/IF, and IP supports orthogonal workflows rather than relying on a single endpoint.
-
BI 2536 Workflow for PLK1-Driven Cancer Assays
2026-08-12
BI 2536 provides a selective way to connect PLK1 inhibition with mitotic arrest, growth suppression, and apoptosis in cancer models. This workflow separates reduced proliferation from true cell killing, improving interpretation of dose–response, cell-cycle, and tumor xenograft experiments.
-
Leucovorin Calcium: Methotrexate Rescue Research
2026-08-11
Leucovorin Calcium, also called calcium folinate, supplies reduced folate cofactors that can bypass methotrexate-related dihydrofolate reductase inhibition in research models. Product specifications support controlled aqueous preparation, cold storage, and prompt use of solutions in cell proliferation and cytotoxicity workflows.
-
RBMS1 Loss Enables Immunity in Triple-Negative Breast Cancer
2026-08-11
The reference study identifies the RNA-binding protein RBMS1 as an upstream regulator of PD-L1 stability in immune-cold triple-negative breast cancer. By destabilizing B4GALT1 mRNA, RBMS1 loss reduces PD-L1 glycosylation and promotes its ubiquitination and degradation, improving cytotoxic T-cell activity and the response to immune-based treatments.
-
Nelfinavir Mesylate in HIV and Ferroptosis Research
2026-08-10
Nelfinavir Mesylate supports two complementary research paths: quantitative HIV-1 protease inhibition assays and mechanistic studies of DDI2-NFE2L1 control during ferroptosis. This guide provides a practical workflow for stock preparation, concentration-response testing, pathway validation, and troubleshooting while separating established evidence from assay-development recommendations.
-
6-Thioguanine Blocks EV71 via BIRC3 Autophagy
2026-08-09
The 2025 BMC Microbiology study identifies 6-thioguanine as a potent in vitro inhibitor of EV71 replication and links its activity to suppression of BIRC3-mediated complete autophagy. Its strong selectivity in HT-29 cells supports further antiviral investigation, while the cell-based design and absence of clinical validation limit immediate therapeutic interpretation.
-
BEND Lipids Improve mRNA and CRISPR Delivery
2026-08-08
The reference study introduces branched endosomal disruptor lipids as an ionizable-lipid architecture that improves hepatic delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complexes, as well as T-cell transfection. Its structure–function analysis links terminal branching to enhanced endosomal penetration and disruption, offering a mechanistic direction for optimizing nonviral nucleic-acid delivery.
-
Oltipraz Workflow for Nrf2 and MASLD Research
2026-08-07
Oltipraz provides a defined small-molecule route to Nrf2-driven phase II enzyme induction, complementing integrated MASLD studies that measure autophagy and ferroptosis. This workflow shows how to connect GST and NQO1 outputs with lipid, inflammatory, and cell-death assays while controlling solubility, timing, and interpretation.